Peer-reviewed veterinary case report
Yorkshire Terrier with brain tumor treated long-term with chemo
By Yun, Taesik et al.·Published in The veterinary quarterly·2021·College of Veterinary Medicine, South Korea·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Characteristics ofF-FDG andF-FDOPA PET in an 8-year-old neutered male Yorkshire Terrier dog with glioma: long-term chemotherapy using hydroxyurea plus imatinib with prednisolone and immunoreactivity for PDGFR-β and LAT1.
- Species:
- dog
Plain-English summary
An 8-year-old neutered male Yorkshire Terrier was brought in for head pressing, balance issues, neck pain, and a lack of eye reflexes. An MRI revealed a tumor in the brain, leading to a diagnosis of glioma. The dog was treated with a combination of hydroxyurea, imatinib, and prednisolone, which significantly improved his neurological symptoms for nearly three years. Unfortunately, the dog eventually showed signs of deterioration and was euthanized after 1155 days, with histopathology confirming the glioma. This case suggests that chemotherapy may be a viable option for treating brain tumors in dogs.
People also search for: Yorkshire Terrier glioma treatment · dog head pressing causes · chemotherapy for dog brain tumor
Abstract
An 8-year-old neutered male Yorkshire Terrier dog presented with head pressing, vestibular ataxia, neck tenderness, and no oculocephalic reflex. A demarcated lesion in the pons was identified on MRI. The patient was tentatively diagnosed with a glioma and was treated with hydroxyurea plus imatinib and prednisolone. After 30 days of therapeutic treatment, the patient showed a clear improvement in neurological signs, which lasted for 1117 days. On day 569 after the initiation of treatment,F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) was performed with no significant findings on visual analysis. The average and maximal standardized uptake values (SUVs) were 1.92 and 2.29, respectively. The tumor-to-normal-tissue (T/N) ratio was 0.97. The first evidence of clinical deterioration was noticed on day 1147. On day 1155, 3,4-dihydroxy-6-[F]-fluoro-l-phenylalanine (F-FDOPA)-PET was performed. High uptake ofF-FDOPA was observed in the intracranial lesion. The mean and maximal SUVs of the tumor were 1.59 and 2.29, respectively. The T/N ratio was 2.22. The patient was euthanized on day 1155 and histopathologic evaluations confirmed glioma (astrocytoma). This case shows that chemotherapy with hydroxyurea plus imatinib may be considered in the treatment of canine glioma. Furthermore, this is the first case describing the application ofF-FDG andF-FDOPA in a dog with glioma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/33745419/